# Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

> **NCT01019694** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 470 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Combivent CFC-MDI
- **DRUG:** Combivent Respimat 20/100 mcg
- **DRUG:** Atrovent HFA 42 mcg + Albuterol HFA 200 mcg

## Key facts

- **NCT ID:** NCT01019694
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 470 (ACTUAL)
- **Last updated:** 2014-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01019694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01019694, "Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01019694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*